DII Data:Stock Market Insights on 20 Sep -Concord Biotech

Below is a summary of the recent activities observed within the Domestic Investments for the clients: Nexpact . Let’s delve into the details below to explore further.

Company Logo	Company	Client Name	Buy/Sell	Qty Traded	Price	Trader Name
	One Global Service Provider	Nexpact	Buy	50K	141.10	Na
	Concord Biotech	Ubs Principal Capital Asia	Sell	740K	2589.86	The Vanguard Group Inc A/c Vanguard Total International Stock Index Fund
	Marksans Pharma	Vanguard Emerging Markets Stock Index Fund A Series Of Vanguard International Equity Index Funds	Buy	2M	316.85	Graviton Research Capital Llp
		Vanguard Total International Stock Index Fund	Buy	2M	316.85	Graviton Research Capital Llp

The 50K shares of One Global Service Provider have been purchased by the by Nexpact through Domestic Investments at a price of ₹141.10 per share.
The 740K shares of Concord Biotech have been sold by the by Ubs Principal Capital Asia through Domestic Investments at a price of ₹2589.86 per shareand it is purchased by The Vanguard Group Inc A/c Vanguard Total International Stock Index Fund at a price of ₹2589.86 per share.
The 2M shares of Marksans Pharma have been purchased by the by Vanguard Emerging Markets Stock Index Fund A Series Of Vanguard International Equity Index Funds through Domestic Investments at a price of ₹316.85 per shareand it is sold by Graviton Research Capital Llp at a price of ₹316.85 per share.
The 2M shares of Marksans Pharma have been purchased by the by Vanguard Total International Stock Index Fund through Domestic Investments at a price of ₹316.85 per shareand it is sold by Graviton Research Capital Llp at a price of ₹316.85 per share.

[my_shortcode values=”One Global Service Provider , Concord Biotech , Marksans Pharma “]

Join our telegram for more updates

Stay Updated with Our YouTube Videos